The largest database of trusted experimental protocols
> Chemicals & Drugs > Amino Acid > Viral Proteins

Viral Proteins

Viral Proeteins: Discover the power of viral proteins with PubCompare.ai's AI-driven platform.
Optimize your research protocols by locating the most effective approaches from literature, preprints, and patents.
Our AI-powered comparisons help you streamline your viral protein research and identify the best products and protocols.
Unleash the potential of viral proteins and take your research to new heights.

Most cited protocols related to «Viral Proteins»

Each metric is computed using sliding windows from 10 to 100 genes wide, starting at every gene along the sequence, and all scores greater than 2 are stored. Local maxima of significance score are then searched and the associated set of genes is defined as a putative viral region. These different predictions (based on the metrics above) are then merged when overlapping (extending the regions to include all predicted windows), leading to a list of putative viral regions associated with a (set of) metric(s). These regions are classified into three categories: (i) category 1 (“most confident” predictions) regions have significant enrichment in viral-like genes or non-Caudovirales genes on the whole region and at least one hallmark viral gene detected; (ii) category 2 (“likely” predictions) regions have either enrichment in viral-like or non-Caudovirales genes, or a viral hallmark gene detected, associated with at least one other metric (depletion in PFAM affiliation, enrichment in uncharacterized genes, enrichment in short genes, depletions in strand switch); and (iii) category 3 (“possible” predictions) regions have neither a viral hallmark gene nor enrichment in viral-like or non-Caudovirales genes, but display at least two of the other metrics with at least one significance score greater than 4. Finally, if a predicted region spans more than 80% of predicted genes on a contig, the entire contig is considered viral. A summary of VirSorter detection types is displayed in Fig. 1B.
Next, higher confidence predictions are used to refine the sequence space search. Specifically, sequences from all open reading frames from category 1 predictions that do not match a viral protein cluster are clustered and added to the reference database (RefSeqABVir or Viromes depending on the initial user choice). This updated database is then used in another round of search by VirSorter. This iteration where category 1 sequences are used to refine the searches is continued until no new genes are added to the database. Once no new genes are added, the final VirSorter output is provided to the user and includes nucleotide sequences of all predicted viral sequences in fasta files, an automatic annotation of each prediction in genbank file format, and a summary table displaying for each prediction the associated category and significance scores of all metrics. By providing the predictions and the underlying significance scoring, users can evaluate each prediction and apply custom thresholds on significance scores through a simple text-parsing script, even for large-scale datasets.
VirSorter is available as an application (App) in the iPlant discovery environment (https://de.iplantcollaborative.org/de/) under Apps/Experimental/iVirus (see Fig. S1 for a step-by-step guide of VirSorter app on iPlant). This application allows users to search any set of contigs for viral sequences using either the RefSeqABVir or the Viromes database. The reference values of VirSorter metrics will be evaluated on the complete set of input sequences, hence mixed datasets should be sorted (when possible) by type of bacteria or archaea in order to get the most accurate result possible. In addition to these reference databases, the VirSorter App on iPlant allows users to input their own reference viral genome sequence already assembled or to-be assembled using iPlant Apps prior to analysis with VirSorter. Assembled sequences are processed as follows: (i) genes are predicted with MetaGeneAnnotator (Noguchi, Taniguchi & Itoh, 2008 (link)), (ii) predicted proteins are clustered with sequences from the user-selected database (either RefSeqABVir or Viromes), and (iii) unclustered proteins are added to the “unclustered” pool. VirSorter scripts are also available through the github repository https://github.com/simroux/VirSorter.git.
Full text: Click here
Publication 2015
Archaea Bacteria Caudovirales CTSB protein, human Genes Genes, vif Genes, Viral Open Reading Frames Proteins Span 80 Viral Genome Viral Proteins Virome
Two reference databases of viral protein sequences were built for VirSorter and are available in the iPlant Discovery Environment (Data/Community_Data/iVirus/VirSorter/Database). The first includes 114,297 proteins from viruses infecting bacteria or archaea in RefSeqVirus genomes (as of January 2014), hereafter named “RefSeqABVir.” Protein clusters (PCs) were defined using MCL clustering (Enright, Van Dongen & Ouzounis, 2002 (link)) of these proteins (inflation 2.0) based on their reciprocal blastp comparisons (threshold of 50 on bit score and 10−03 on E-value). The 9,735 PCs with at least 3 sequences were used to define a profile database searchable with HMMER3 tools (Eddy, 2011 (link)). The remaining 34,668 unclustered sequences were formatted for a blastp search. All PCs that did not contain any sequences from Caudovirales and unclustered sequences from viruses other than Caudovirales were marked as “Non-Caudovirales.”
The RefSeqABVir database was then augmented by virome sequences sampled from freshwater, seawater, and human gut, lung and saliva, resulting in an extended version of the reference database (hereafter named “Viromes”) which includes both virome and RefSeqABVir sequences. This combined reference dataset should help to detect new viruses for which no cultivated reference sequence is available. When only raw reads were available, viromes were assembled using Newbler (threshold of 98% identity on 35bp). The resulting contigs were then checked for the presence of cellular genome sequences, and only the 68 viromes for which no 16S rRNA genes were retained (see Table S1 for a complete list of these viromes). Contigs assembled from these 68 viromes were then manually inspected (through annotations generated by Metavir; Roux et al., 2014a (link)) and revealed no identifiable cellular genome sequences (i.e., no sequence contained more than 2 genes that matched a cellular genome and were not found in any known virus). A total of 146,521 complete predicted proteins from this quality-controlled dataset were then clustered with the 114,297 proteins from RefSeqABVir, leading to 15,673 clusters with 3 sequences or more, and 88,052 unclustered sequences. PCs from the combined Viromes database were used to create a profile database searchable with HMMER3, and the 34,338 unclustered sequences from RefseqABVir were formatted for BLAST search (unclustered sequences from viromes were not added to the database to prevent the inclusion of contaminating sequences).
Within these databases, viral “hallmark” genes were defined though a text-searching script looking for “major capsid protein,” “portal,” “terminase large subunit,” “spike,” “tail,” “virion formation” or “coat” annotations. After a manual curation step removing genes with more general annotation such as “protease” or “chaperone,” 826 PCs or single genes were identified as “viral hallmark genes.” This latter point meant removing domains also matching “protease” or “chaperone” domains and was conducted to minimize false positives for our viral hallmark genes category by extra-cautiously avoiding PCs that might include domains that could derive from either both viruses or microbes.
Full text: Click here
Publication 2015
Bacteria Capsid Proteins Caudovirales Cells Gene Annotation Genes Genes, Viral Genome Genome, Archaeal Homo sapiens Lung Molecular Chaperones Peptide Hydrolases Proteins Protein Subunits Ribosomal RNA Genes RNA, Ribosomal, 16S Saliva Tail terminase Viral Proteins Virion Virome Virus
Predicted proteins from reference viral genomes from NCBI and VOG database viral proteins were combined to generate v-scores, which resulted in a total of 633,194 proteins. Redundancy was removed from the viral protein dataset using CD-HIT (v4.6) [56 (link)] with an identity cutoff of 95%, which resulted in a total of 240,728 viral proteins. This was the final dataset used to generate v-scores. All KEGG HMM profiles were used to annotate the viral proteins. A v-score for each KEGG HMM profile was determined by the number of significant (e-value < 1e−5) hits by hmmsearch, divided by 100, and a maximum value was set at 10 after division. The same v-score generation was done for Pfam and VOG databases. Any HMM profile with no significant hits to the virus dataset was given a v-score of zero. For KEGG and Pfam databases, any annotation that was given a v-score above zero and contained the keyword “phage” was given a minimum v-score of 1. To highlight viral hallmark genes, any annotation within all three databases with the keyword portal, terminase, spike, capsid, sheath, tail, coat, virion, lysin, holin, base plate, lysozyme, head, or structural was given a minimum v-score of 1. Non-prokaryotic virus annotations (e.g., reovirus core-spike protein) were not considered. Each HMM is assigned a v-score and represents a metric of virus association (i.e., do not take into account virus specificity or association with non-viruses) and are manually tuned to put greater weight on viral hallmark genes (Additional File 4: Table S4). Overall, annotations that are likely non-viral will have a low v-score whereas annotations that are commonly associated with viruses will have a high v-score. Raw HMM table outputs for v-score generation can be found in Additional Files 5, 6, and 7 for KEGG, Pfam, and VOG, respectively (Additional File 5: Table S5, Additional File 6: Table S6, and Additional File 7: Table S7).
Full text: Click here
Publication 2020
Bacteriophages Capsid Proteins Genes, Viral Genome Head lysin, gastropoda M protein, multiple myeloma Muramidase Prokaryotic Cells Proteins Reoviridae Satellite Viruses Staphylococcal Protein A Tail terminase Viral Genome Viral Proteins Virion Virus
NCBI protein annotations (RefVirus) were first automatically curated (no upper case except in gene names, correction of typos, etc.). Phages for which all protein annotations was only an uninformative list (‘hypothetical protein GP1’, ‘hypothetical protein GP2’, etc.) were considered as unannotated. These protein annotations were first combined to determine an annotation for PHROGs. To refine this annotation, the 38 880 PHROGs were compared to different databases. PHROG profiles were compared to Pfam domains (version of jan 2018; 19 (link)) and UNICLUST (20 (link)) and individual viral protein were compared to proteins in KEGG Orthologous groups (KOs; version of jan 2018) using MMseq (bit-score>50, coverage >50%). Manual curation of the collected annotations and similarities allowed to extract a single annotation per PHROG.
Publication 2021
Bacteriophages Genes Protein Annotation Proteins Viral Proteins
The 25,000 viral protein families (VPFs) used to identify UViGs were queried against the ViralZone database (12 (link)), where viral hosts were predicted at different taxonomic levels. 11 400 VPFs had at least one hit to the virus genomes and an average of 6.8 hits per model was calculated. For each VPF, a score value (between 0 and 1) was obtained dividing the total number of hits with a uniform distribution (only present in a single host domain) by the total number of VPF hits [i.e. score = (#uniform hits/#total hits)]. In the cases where the total number of hits was below the average number of hits, we corrected the score as follows: [(#uniform hits/#total hits) × (#total hits/average #hits)].
3788 VPFs were assigned with the maximum 1.0 score, representing those models found in at least seven known viral genomes and with a uniform domain distribution. The presence of these VPFs across the UViGs allowed us to separate 65% of the viral genomes into prokaryotic (bacteriophages and archaeal viruses), or eukaryotic viruses.
This approach has been benchmarked using the host assignment of the viral genomes containing pVOGs (13 (link)) with homology to our 1.0-score VPFs (2,037 pVOGs) with ≥95% homology based on hhsearch (14 (link)). Our classification was consistent with the classification in the pVOG database in all 98.6% of the cases. The remaining 1.4% resulted in viruses annotated as ‘archaea-bacteria’ viruses in the pVOG database that were identified as either bacteria or archaea using our approach. Thus, we can estimate that there was a 100% consistency of this method separating prokaryotic and eukaryotic viruses.
Full text: Click here
Publication 2018
Archaea Archaeal Viruses Bacteria Bacteriophages Eukaryota Prokaryotic Cells Viral Genome Viral Proteins Virus

Most recents protocols related to «Viral Proteins»

Example 4

An overview of the immunization strategies for lectin-binding proteins, such as galectin-3, is shown in Table 18.

BALB/c mice were immunized with 2 mg/kg mRNA, complexed with LNPs, or 20 μg recombinant protein as indicated in Table 18. Plasma anti-galectin-3 IgG titers were assayed 7 days after the final boost, which was delivered at day 55.

FIG. 3 shows that the use of galectin-3 mRNA as a final boosting agent resulted in a significantly higher target-specific IgG titer than when purified recombinant protein (a traditional immunogen) was used. This effect was observed regardless of whether the antigens were delivered subcutaneously or intravenously.

Hybridomas producing galectin-3-specific antibodies were generated, and high affinity monoclonal anti-galectin-3 antibodies were obtained from further screens.

TABLE 18
Priming ImmunizationBoostFinal Boost
(Day 0)(Day 7)(Day 55)
mRNA (I.V.)mRNA (I.V.)mRNA (I.V.)
mRNA (I.V.)mRNA (I.V.)Recombinant protein
(I.V.)
mRNA (S.C.)mRNA (S.C.)mRNA (S.C.)
mRNA (S.C.)mRNA (S.C.)Recombinant protein
(S.C.)
Summary of the Hit Rates Attainable by mRNA-Mediated Immunization

Table 19 provides a target protein-specific summary of the total number of hybridoma wells (generally about one third (⅓) of these wells contain hybridomas) screened and the number of confirmed target-specific antibodies obtained from those hybridomas wells following the use of lipid-encapsulated mRNA as an immunogen.

Table 20 provides a comparison of mRNA-LNP immunization methods with other conventional methods of immunization by number of hybridomas producing target-specific antibodies. In general, these data suggest that mRNA-LNP immunization is an effective method for inducing an immune response to a target protein antigen and for obtaining a higher number/rate of target protein-specific antibodies. In particular, these results confirm that mRNA-LNP immunization is surprisingly more effective than conventional immunization methods for obtaining antibodies specific for transmembrane proteins, e.g., multi-pass transmembrane proteins, such as GPCRs, which are difficult to raise antibodies against, and for poorly immunogenic proteins (e.g., proteins which produce low or no detectable target-specific IgGs in plasma of animals immunized with traditional antigen).

TABLE 19
Number of
Number ofhybridomas
hybridomaproducing
Proteinwellstarget-specific
targetType of proteinscreenedantibodies
RXFP1Multi-pass Transmembrane20240207
protein/GPCR
SLC52A2Multi-pass Transmembrane12880228
protein
ANGPTL8Soluble protein22816542
TSHRTransmembraneTBD130
protein/GPCR
APJTransmembrane22080230
protein/GPCR
GP130Single-pass Transmembrane23920614
protein

TABLE 20
Method of immunization and number of hybridomas producing
target-specific antibodies
Whole Virus-likeProtein/
ProteinType ofmRNA-cellsparticlesCDNApeptide
targetproteinLNP1onlyonlyonlyonly
RXFP1GPCR/20766NDNDND
multi-pass
SLC52A2multi-228NSTNSTNDNST
pass
TSHRGPCR/130NDND42413
multi-pass
APJGPCR/230 94621 ND
multi-pass
1Immunization with mRNA-LNP alone or in combination with another antigen format (e.g., protein/peptide).
2Sanders et al. 2002 Thyroid stimulating monoclonal antibodies Thyroid 12(12): 1043-1050.
3Oda et al. 2000. Epitope analysis of the human thyrotropin (TSH) receptor using monoclonal antibodies. Thyroid 10(12): 1051-1059.
ND—Not determined; antigen format not tested
NST—No specific titers detected. Because no target-specific IgG titers were detectable in plasma, hybridoma generation was not initiated on these groups.

In general, successful generation of hybridomas producing antigen-specific antibodies have been achieved for at least 15 different targets utilizing mRNA-LNP immunization methods as exemplified herein. These results show that the mRNA immunization methods described herein are capable of eliciting an immune response against a wide range of antigens (e.g., transmembrane proteins, for example multi-pass transmembrane proteins, such as GPCRs) in host animals, and are effective methods for producing high affinity monoclonal antibodies, which can serve as parentals for generation of chimeric variants, humanized variants, and affinity matured variants.

Full text: Click here
Patent 2024
Animals anti-IgG Antibodies Antigens Binding Proteins Cells Chimera DNA, Complementary Epitopes Galectin 3 Histocompatibility Antigens Class II Homo sapiens Hybridomas Integral Membrane Proteins Lectin Lipids Mice, Inbred BALB C Monoclonal Antibodies Parent Peptides Plasma Proteins Protein Targeting, Cellular Recombinant Proteins Response, Immune RNA, Messenger Soluble Glycoprotein 130 Thyroid Gland Thyrotropin Thyrotropin Receptor Vaccination Viral Proteins
The successfully prepared ligand and protein molecules were docked in the Xtra Precision Docking Mode. It was used to determine the strength of interactions between viral proteins and (R)-(+)-rosmarinic acid, specifically to know binding affinities and inhibition constants between them. To assess the effectiveness of (R)-(+)-rosmarinic acid as a potential ligand, docking metrics including docking scores, hydrophobic interactions, hydrogen bonding (side and back chains), π–π stacking, and salt bridge contacts were examined (Vijayakumar et al. 2016 (link)).
Publication 2023
Hydrophobic Interactions Ligands Proteins Psychological Inhibition rosmarinic acid Sodium Chloride Viral Proteins
Initially, (R)-(+)-rosmarinic acid was chosen as a ligand molecule and retrieved from the chemical database to find out its antiviral potential against the proteins of dengue and herpes viruses. Similar to the ligand, the viral proteins were retrieved from the protein database (www.rcsb.com) as in crystallographic form to dock with (R)-(+)-rosmarinic acid. The alphanumeric identities of the proteins were 1F5Q murine gamma herpesvirus cyclin complexed to human cyclin-dependent kinase 2 (Card et al. 2000 (link)), 2J7W dengue virus NS5 RNA-dependent RNA polymerase domain complexed with 3’dGTP (Yap et al. 2007 (link)), and 4OIG dengue virus nonstructural protein NS1 (Edeling et al. 2014 (link)).
Publication 2023
Antiviral Agents CDK2 protein, human Crystallography Cyclins Dengue Fever Dengue Virus deoxyguanosine triphosphate Gamma Rays Herpesviridae Ligands Mus Proteins RNA-Directed RNA Polymerase rosmarinic acid Rumex Simplexvirus Viral Nonstructural Proteins Viral Proteins
Complete viral protein sequences were downloaded from two publicly available databases, NCBI (Brister et al. 2015 (link)) and Viper (Pickett et al. 2012 (link)), respectively. NS1 sequences were retrieved and filtered to obtain a set of complete and unique sequences. SE (Litwin and Jores 1992 ) was calculated to understand the diversity at each amino acid position. This study's reference strains were as follows: DENV1: Accession number KM204119.1, DENV2: Accession number U87411.1, DENV3: Accession number KU050695.1 and DENV4: Accession number KR011349.2 were retrieved from NCBI. Subsequently, an intense literature survey was done to identify structurally and functionally critical residues. A Python script was written to analyze the temporal and geographical distribution of NS1.
Publication 2023
Amino Acids Amino Acid Sequence Python Strains Viral Proteins
The lentiviral vector used to co-express 2-E+2-3a was LV-E3a (Vectorbuilder ID VB210112-1153ufz) and its respective control vector LV-EV (Vectorbuilder ID VB210112-1153ufz). The LV-E3a vector contains the cytomegalovirus (CMV) promoter, the 2-E+2-3a viroporins obtained from Gordon et al., 2020 (18 (link)) separated by a 2A peptide site, and terminated by a SV40 late polyA sequence cloned into the LV-EV vector. The viroporin sequences deduced from the protein sequences were modified by adding an ATG codon 5’ and three N-terminal FLAG-tags added to the 3’ end of each viral protein. LV-EV is an empty vector.
The lentiviral vector expressing our mCAT and its respective control vector were LV-mCAT (VectorBuilder 210909-1242kdf) and LV-EV (VectorBuilder 900122-0484ubz). The LV-mCAT vector includes the EFS promoter, EGFP, 2A peptide site, mCAT, and SV40 late polyA sequence. The LV-EVcontrol vector lacks the EGFP and mCAT sequences.
Full text: Click here
Publication 2023
Amino Acid Sequence Cloning Vectors Codon Cytomegalovirus Peptides Poly A Simian virus 40 Viral Proteins Viroporin Proteins

Top products related to «Viral Proteins»

Sourced in United States, China, Germany, United Kingdom, Canada, Japan, France, Italy, Switzerland, Australia, Spain, Belgium, Denmark, Singapore, India, Netherlands, Sweden, New Zealand, Portugal, Poland, Israel, Lithuania, Hong Kong, Argentina, Ireland, Austria, Czechia, Cameroon, Taiwan, Province of China, Morocco
Lipofectamine 2000 is a cationic lipid-based transfection reagent designed for efficient and reliable delivery of nucleic acids, such as plasmid DNA and small interfering RNA (siRNA), into a wide range of eukaryotic cell types. It facilitates the formation of complexes between the nucleic acid and the lipid components, which can then be introduced into cells to enable gene expression or gene silencing studies.
Sourced in United States, Germany, China, United Kingdom, Morocco, Ireland, France, Italy, Japan, Canada, Spain, Switzerland, New Zealand, India, Hong Kong, Sao Tome and Principe, Sweden, Netherlands, Australia, Belgium, Austria
PVDF membranes are a type of laboratory equipment used for a variety of applications. They are made from polyvinylidene fluoride (PVDF), a durable and chemically resistant material. PVDF membranes are known for their high mechanical strength, thermal stability, and resistance to a wide range of chemicals. They are commonly used in various filtration, separation, and analysis processes in scientific and research settings.
Sourced in United States, China, Germany, United Kingdom, Switzerland, Japan, France, Italy, Spain, Austria, Australia, Hong Kong, Finland
The Dual-Luciferase Reporter Assay System is a laboratory tool designed to measure and compare the activity of two different luciferase reporter genes simultaneously. The system provides a quantitative method for analyzing gene expression and regulation in transfected or transduced cells.
Sourced in United States, China, Germany, Japan, United Kingdom, France, Canada, Italy, Australia, Switzerland, Denmark, Spain, Singapore, Belgium, Lithuania, Israel, Sweden, Austria, Moldova, Republic of, Greece, Azerbaijan, Finland
Lipofectamine 3000 is a transfection reagent used for the efficient delivery of nucleic acids, such as plasmid DNA, siRNA, and mRNA, into a variety of mammalian cell types. It facilitates the entry of these molecules into the cells, enabling their expression or silencing.
Sourced in United States, United Kingdom, Germany, China, Japan, Canada, France, Switzerland, Italy, Australia, Belgium, Spain, Denmark, Ireland, Netherlands, Holy See (Vatican City State), Israel
Opti-MEM is a cell culture medium designed to support the growth and maintenance of a variety of cell lines. It is a serum-reduced formulation that helps to reduce the amount of serum required for cell culture, while still providing the necessary nutrients and growth factors for cell proliferation.
Sourced in United States, Switzerland, China, Japan, Germany, United Kingdom, France, Canada
PsPAX2 is a packaging plasmid used for the production of lentiviral particles. It contains the necessary genes for lentiviral packaging, but does not contain the viral genome. PsPAX2 is commonly used in lentiviral production workflows.
Sourced in United States, Germany, Italy, United Kingdom, Canada, France, China, Switzerland, Japan, Spain, Australia, Sweden, Portugal, Israel, Netherlands, Belgium
Nitrocellulose membranes are a type of laboratory equipment designed for use in protein detection and analysis techniques. These membranes serve as a support matrix for the immobilization of proteins, enabling various downstream applications such as Western blotting, dot blotting, and immunodetection.
Sourced in United States, United Kingdom, Germany, Japan, Canada, France, China, Morocco, Italy
PNGase F is an enzyme that cleaves the bond between the asparagine residue and the N-acetylglucosamine residue in N-linked glycoproteins. It is commonly used in the analysis and characterization of glycoproteins.
Sourced in United States, Germany, United Kingdom, Japan, China, France, Canada, Spain, Belgium, Italy, Australia, Austria, Denmark, Netherlands, Switzerland, Ireland, New Zealand, Portugal, Brazil, Argentina, Singapore, Poland, Ukraine, Macao, Thailand, Finland, Lithuania, Sweden
Hoechst 33342 is a fluorescent dye that binds to DNA. It is commonly used in various applications, such as cell staining and flow cytometry, to identify and analyze cell populations.
Sourced in United States, United Kingdom, Germany, China, Australia, Switzerland, France, Italy, Canada, Spain, Japan, Belgium, Sweden, Lithuania, Austria, Denmark, Poland, Ireland, Portugal, Finland, Czechia, Norway, Macao, India, Singapore
The Pierce BCA Protein Assay Kit is a colorimetric-based method for the quantification of total protein in a sample. It utilizes the bicinchoninic acid (BCA) reaction, where proteins reduce Cu2+ to Cu+ in an alkaline environment, and the resulting purple-colored reaction is measured spectrophotometrically.

More about "Viral Proteins"

Viral proteins are a fascinating and crucial area of study in the field of molecular biology and virology.
These proteins play pivotal roles in the life cycle, replication, and propagation of viruses, making them a prime target for research and therapeutic interventions.
Viral proteins encompass a wide range of subtopics, including capsid proteins, envelope proteins, and non-structural proteins.
Capsid proteins form the protective shell that encloses the viral genome, while envelope proteins are responsible for facilitating host cell entry and attachment.
Non-structural proteins, on the other hand, are involved in various processes such as viral genome replication, transcription, and immune evasion.
Researchers often utilize advanced techniques and tools to study viral proteins, such as the Lipofectamine 2000 transfection reagent, which enables the efficient delivery of genetic material into cells.
PVDF (polyvinylidene fluoride) and nitrocellulose membranes are commonly employed in Western blotting analyses to detect and quantify viral protein expression.
The Dual-Luciferase Reporter Assay System is another powerful tool that allows for the measurement of viral promoter activity and gene expression.
Additionally, the Lipofectamine 3000 transfection reagent and Opti-MEM serum-free medium are often used in viral protein research to optimize transfection efficiency and cell viability.
The PsPAX2 lentiviral packaging plasmid is a vital component in the production of lentiviral particles, which can be used to deliver genetic material, including viral proteins, into target cells.
The PNGase F enzyme is employed to remove N-linked glycans from viral proteins, aiding in their structural and functional characterization.
Hoechst 33342, a fluorescent DNA-binding dye, is commonly used to visualize and quantify viral DNA content, while the Pierce BCA Protein Assay Kit is a reliable method for determining the concentration of viral proteins in samples.
By leveraging these tools and techniques, researchers can gain a deeper understanding of viral proteins, their structures, functions, and interactions with host cells.
This knowledge can then be applied to the development of effective antiviral therapies, the design of improved viral vectors for gene delivery, and the advancement of our overall understanding of virus-host dynamics.